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The gut microbiota composition has been associated with several
hallmarks of metabolic syndrome (e.g., obesity, type 2 diabetes,
cardiovascular diseases, and non-alcoholic steatohepatitis).
Growing evidence suggests that gut microbes contribute to the
onset of the low-grade inﬂammation characterising thesemetabolic
disorders via mechanisms associated with gut barrier dysfunctions.
Recently, enteroendocrine cells and the endocannabinoid system
have been shown to control gut permeability and metabolic endo-
toxaemia. Moreover, targeted nutritional interventions using non-
digestible carbohydrates with prebiotic properties have shown
promising results in pre-clinical studies in this context, although
human intervention studies warrant further investigations. Thus, in
this review, we discuss putativemechanisms linking gutmicrobiota
and type 2 diabetes. These data underline the advantage of inves-
tigating and changing the gut microbiota as a therapeutic target in
the context of obesity and type 2 diabetes.
 2013 Elsevier Ltd. Open access under CC BY-NC-ND license.Introduction
In 1947, Jean Vague was the ﬁrst to propose the android obesity phenotype as a common feature in
metabolic abnormalities associated with type 2 diabetes and cardiovascular disease [1]. Many years
later, many international organisations and expert groups [2–5] have agreed on most of the essentialde Louvain, Louvain Drug Research Institute, Metabolism and Nutrition
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them as metabolic syndrome. Although these symptoms differ in terms of the number and type of
criteria, the deﬁnition of metabolic syndrome includes obesity, glucose homeostasis disorders (e.g.,
type 2 diabetes, impaired fasting glucose, glucose intolerance, and insulin resistance), lipid homeo-
stasis disorders (i.e., dyslipidaemia) and cardiovascular diseases risk factors (e.g., hypertension and
ﬁbrolysis disorders) [6].
Today, the clinical management of obesity is based on targeting obesity, insulin resistance and
associated disorders. Therapeutic, nutritional and behavioural managements are proposed. While a
weight loss of 5–10% of the initial body weight can enhance insulin sensitivity in overweight/obese
individuals who are insulin resistant, only some metabolic abnormalities return to the levels seen in
insulin-sensitive subjects [7,8]. Whereas, to date, drugs have not been particularly effective for the
treatment of obesity, recent ﬁndings devoted to understanding the biochemical pathways related to
the development of obesity have provided new targets.
Among these new targets, growing evidence supports the idea that the increased prevalence of
obesity and type 2 diabetes cannot be attributed solely to changes in the human genome, nutritional
habits, or the reduction of physical activity in our daily lives [9]. In the vast majority of adults, both the
qualitative and quantitative composition of food intake varies considerably from meal to meal and
from day to day, whereas adiposity and body weight are remarkably constant despite various short-
term variations in the energy balance. It is worth noting that when recording food intake and activ-
ity within a period including several meals, most individuals are able to compensate their cumulative
energy intake with their energy expenditure with great precision [10]. Such an active process stabilises
the amount of energy stored as fat in the body. However, an excess of energy intake by less than 1%
compared with the daily energy expenditure can lead to a detrimental increase in body weight and
metabolic complications over the long term (several years) [11]. Consequently, all the mechanisms
inﬂuencing calorie ingestion and subsequent harvesting should contribute to a balance in the body
weight; however, the majority of molecular targets involved in this process are unknown.
Gut microbiota as novel key organ involved in metabolism
One speciﬁc environmental factor evolving with us from birth and our dietary habits has been
shown to contribute to energy homeostasis. This factor, the so-called gut microbiota, has also been
shown to be involved in several intestinal biological functions, such as the defence against pathogens,
immunity, the development of the intestinal microvilli and the degradation of non-digestible poly-
saccharides [12,13]. Several elegant reports have suggested that the gut microbiota exerts a crucial role
in the development of fat mass and altered energy homeostasis. The earliest evidence supporting this
hypothesis was from a study revealing that germ-free mice (mice raised in the absence of any mi-
croorganisms) are leaner compared with mice that harboured microbiota since birth. Importantly, the
conventionalisation of germ-free mice with a gut microbiota induced an increase in fat mass and in-
sulin resistance. This study revealed the gut microbiota to be an environmental factor that regulates fat
storage [14]. One of the proposed mechanisms is that the gut microbiota has the capacity to increase
the energy harvested from the diet. Moreover, its ability to modulate host signalling pathways could
inﬂuence the host energy balance and hostmetabolism [14–17].We [18] and others have demonstrated
that the gut microbiota plays a major role in the onset of insulin resistance and type 2 diabetes by
triggering low-grade inﬂammation (Fig. 1) [17–19]. Although not included in the deﬁnition of meta-
bolic syndrome, low-grade inﬂammation is a common feature characterising obesity and several
metabolic disorders. However, how the gut microbiota contributes to the development of low-grade
inﬂammation remains to be understood.
Among the potential mechanisms, we recently found that in pathological conditions, such as
obesity and type 2 diabetes, the gut microbiota can control the host metabolism and contributes to
development of low-grade inﬂammation (Fig. 1) [18,20–24]. We have contributed to the discovery of
key elements linking the gut microbiota to host metabolism, low-grade inﬂammation and metabolic
disorders in obesity and type 2 diabetes [18,21,22]. Among the mechanisms, we deﬁned gut
microbiota-derived lipopolysaccharide (LPS) as a key molecule involved in the early development of
inﬂammation and metabolic diseases (Fig. 1) [18,21]. Indeed, LPS is a powerful proinﬂammatory
Fig. 1. (A) In physiological condition, the composition and the activity of the gut microbiota is stable. The gut barrier function is
maintained via several mechanisms such as the appropriate localisation and distribution of tight junction proteins (claudin, ZO-1
and occludin), a normal endocannabinoid system tone and LPS detoxiﬁcation by intestinal alkaline phosphatase. Altogether,
these factors contribute to the maintenance of appropriate energy, lipid and inﬂammatory homeostasis. (B) Obesity and type-2
diabetes are characterised by gut barrier alterations leading to disruption in the gut microbiota-host symbiotic relationship. This
increase in gut permeability results from different disturbances: 1 alterations in the gut microbiota composition and/or activity; 2
alterations in the expression, localisation and distribution of tight junction proteins (claudin, ZO-1 and occludin) leading to an
increase in paracellular gut permeability; 3 overactivation of the CB1 receptor; 4 a decrease in intestinal alkaline phosphatase
activity leading to a decrease in LPS detoxiﬁcation. Gut barrier alterations are responsible for metabolic endotoxaemia leading to
low-grade inﬂammation and metabolic disorders (i.e., alterations of glucose and lipid homeostasis). Prebiotic treatment restores
these alterations in the gut microbiota, modulates enteroendocrine peptides and improves gut permeability these changes are
associated with a reduction in low-grade inﬂammation and the restoration of glucose and lipid homeostasis in obesity and type 2
diabetes.
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with the death of Gram-negative bacteria.Metabolic endotoxaemia
The concept of metabolic endotoxaemia (i.e., increased plasma LPS levels) was ﬁrst deﬁned in a
series of experiments in mice [18,21]. We discovered that both fat feeding and a high-fat diet increase
the plasma LPS levels (2- to 5-fold, corresponding to one to two orders of magnitude lower than the
levels attained in endotoxic shock or infections) [18]. This concept has been generalised to different
models of genetic obesity and type 2 diabetes (ob/ob and db/db) [22–25]. Notably, the relationship
among fat feeding, obesity, type 2 diabetes and LPS was subsequently conﬁrmed in numerous studies
performed in human subjects [26–35]. Similar to metabolic endotoxemia, the translocation of ‘live’
bacteria to host tissues has recently been proposed as a feature of diabetes and deﬁned as metabolic
bacteraemia. The authors suggested that ‘live’ Gram-negative bacteria may be found in tissues prior to
diabetes onset [36,37]. In addition to rodent studies [36], they found in a cohort of 3280 subjects that
the 16S rDNA concentration was higher in humans with a predisposition for diabetes. No difference
was observed regarding obesity. Importantly, all the participants (with or without diabetes) shared a
core blood microbiota composed predominantly (85–90%) by the phylum Proteobacteria. In this study,
the researchers proposed that the amount of the 16S rDNA gene in the blood may serve as a
biomarker of diabetes risk [37]. However, this ﬁnding warrants further investigation.
In the next chapter, we will discuss several recent mechanisms contributing to the development of
metabolic endotoxaemia, low-grade inﬂammation, type 2 diabetes and insulin resistance associated
with obesity.Origin of metabolic endotoxaemia: insights into the gut microbiota and gut barrier function
Given the importance of endotoxaemia and low-grade inﬂammation in the onset of metabolic
disorders associated with obesity, identifying the origin and underlying mechanisms is of the utmost
importance.
Obesity and type-2 diabetes are associated with gut microbiota alterations
Today, the pathology of obesity is recognised to be associated with changes in the gut microbiota
diversity and composition (i.e., changes in abundance at the level of phyla, genus or species). The ﬁrst
study showing these gut microbiota alterations was performed in genetically obese mice (ob/obmice)
and revealed an increase in Firmicutes and a decrease in Bacteroidetes, which are the 2 dominant phyla
of the gut microbiota [15,38]. Our group was the ﬁrst to demonstrate that a high-fat diet is associated
with gut microbiota alterations in mice, i.e., a decrease in one group of Firmicutes-related bacteria
(Eubacterium rectale and Blautia coccoides) levels, biﬁdobacteria levels and Bacteroides-like mouse in-
testinal bacteria levels [18]. Since these pioneering studies, various reports have characterised the gut
microbiota in mouse models of obesity, with most of the results highlighting an increase in Firmicutes
and a decrease in Bacteroidetes associated with obesity [16,25,39,40].
In humans, whether the pathology of obesity and type-2 diabetes is also associated with changes in
the abundance of the principal bacterial phyla, the increase in the Firmicutes/Bacteroidetes ratio in
obese patients remains a matter of debate [41–46]. Furthermore, human studies have revealed changes
in the speciﬁc gender or species associated with obesity and type 2 diabetes. The Biﬁdobacterium
abundance appears to be lower in overweight, obese or type 2 diabetic patients than in lean subjects
[44,45]. Another species decreased by type 2 diabetes is Faecalibacterium prausnitzii [47]. Interestingly,
Biﬁdobacterium and Faecalibacterium prausnitzii are correlated with anti-inﬂammatory effects [47,48].
Moreover, a follow-up study indicated that the microbial composition during childhood may predict
overweightness [49]. The authors identiﬁed a higher level of Staphylococcus aureus and lower level of
biﬁdobacteria in the faecal samples of children who became overweight. In a recent study, Vrieze et al
have shown that infusion of intestinal microbiota from lean healthy donor temporarily improves in-
sulin sensitivity in individuals with metabolic syndrome [50].
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obesity and type 2 diabetes, but numerous questions are debated or unanswered. We are still inves-
tigating the following question: are gut microbiota alterations associated with the diet or with the
pathology of obesity itself? Moreover, whether gut microbiota alterations in early life are associated
with an increase in the susceptibility to overweightness and obesity [49] and whether the gut
microbiota changes observed in obesity and type 2 diabetes are a cause or a consequence of the pa-
thology remain unknown [51]. Altogether, these data reveal an existing association between gut
microbiota and the pathology of obesity and type 2 diabetes in humans.
Mechanisms linking the gut microbiota, metabolic endotoxaemia and gut permeability
One of the principal roles of the intestine is to enable the symbiotic relationship between the gut
microbiota and host while preventing a host tissue microbiota invasion. However, gut barrier
dysfunction may represent an open door for microbes or for molecules derived from bacteria from the
intestinal lumen (e.g., LPS, peptidoglycans, and ﬂagellin) (Fig. 1). Emerging evidence suggests that gut
barrier disruption could be responsible for the metabolic endotoxaemia present in obesity and type 2
diabetes. First, we and others have observed that this pathology is associated with an increase in gut
permeability in different mouse models of obesity (Fig. 1) [22,52–54]. From a mechanistic point of
view, the alteration of gut permeability has been associated with an increase in paracellular
permeability. This paracellular permeability is regulated by multi-protein complexes, namely, the
tight-junction proteins linking epithelial cells together (e.g., claudin, occludin, and zonula occludens
1) (Fig. 1) [55]. We and others have demonstrated that the increase in gut permeability observed in
obese mice may be associated with an alteration in the expression, localisation and distribution of
two tight-junction proteins (occludin and zonula occludens 1) in the small intestine [22,23,52,54].
Moreover, we have shown that changes in the gut microbiota by antibiotics increased the mRNA
expression of zonula occludens 1 and reduced gut permeability and metabolic endotoxaemia in high-
fat diet-induced obese mice (Fig. 1) [22]. These results indicate the involvement of the gut microbiota
in the inception of gut barrier alterations and thus in metabolic endotoxaemia in obesity and type 2
diabetes.
More recently, the endocannabinoid system (eCB) has been proposed to be involved in the regu-
lation of gut barrier function during obesity [24]. This system is composed of endogenous bioactive
lipids that exert most of their functions by activating two G protein-coupled receptors, namely,
cannabinoid receptor 1 (CB1) and 2 (CB2). CB1 and CB2 are expressed throughout the gastrointestinal
tract at various levels, depending on the segment [56]. The most studied endocannabinoid lipids are
anandamide (AEA), an N-arachidonoylethanolamine, and 2-arachidonoylglycerol (2-AG). Both lipids
are CB1 and CB2 ligands, with anandamide having a greater afﬁnity for CB1, and have been proposed to
be involved in the regulation of gut barrier functions [24,56,57]. However, the gut barrier regulation in
obesity appears to be CB1 dependent, as CB1 antagonists decrease gut permeability and metabolic
endotoxaemia in genetically obese and type 2 diabetic mice [24]. Moreover, the eCB system exerts
these effects on epithelial permeability by altering the distribution of tight junction proteins [24].
Interestingly, we have shown that the gut microbiota itself can regulate CB1 because antibiotic treat-
ment decreases themRNA expression of this receptor in the colon of mice (Fig.1) [24]. Altogether, these
results suggest that the gut microbiota could induce their effects on gut barrier alterations and
metabolic endotoxaemia through the eCB in the pathology of obesity and type 2 diabetes.
In addition to the important role of a physical barrier played by the intestine, other mechanisms are
implicated in enabling the symbiotic relationship between the gut microbiota and the host (e.g., the
immune system). Among them, recent data have implicated intestinal alkaline phosphatase (IAP).
Although this enzyme is known to be involved in the breakdown of dietary lipids, it also plays an
important role in LPS detoxiﬁcation by dephosphorylating the lipid portion of the LPS (Fig. 1) [58].
Interestingly, the expression of IAP has been shown to be controlled by the gut microbiota [59].
Moreover, obesity appears to be associated with a decrease in IAP activity even though the IAP activity
is differentially modulated depending on the type of fatty acid [53] [60]. Thus, modiﬁcations of the IAP
activity by a high-fat diet, gut microbiota or other compounds contribute to the alterations in the gut
barrier functions in obesity and type 2 diabetes. Moreover, an increase in IAP activity is associated with
a reduction in metabolic endotoxaemia (Fig. 1) [61].
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type 2 diabetes. Any gut barrier disruptionsmay increase the absorption of bacterial parent compounds
(e.g., LPS), leading tometabolic endotoxaemia, inﬂammation andmetabolic diseases. Although this link
is well established in a mouse model of obesity, more studies are needed to conﬁrm the involvement of
gut microbiota alterations and gut barrier functions in the metabolic endotoxaemia associated with
obesity and type 2 diabetes in humans.
The role of prebiotics in this context from bench to bedside in brief
Pre-clinical studies
Because the gut microbiota are crucial actors in the pathology of obesity and type 2 diabetes, gut
microbiota modulations are viewed as an interesting tool to treat these diseases. Based on this hy-
pothesis, we have shown that gut microbiota modulations using prebiotics (i.e., short chain inulin-type
fructans, oligofructose or wheat-derived arabinoxylan oligosaccharides) improve gut barrier functions,
metabolic endotoxaemia and inﬂammation in obesity and type 2 diabetes (Fig. 1) [23,62,63]. These
modulations are associated with a trophic effect on the intestine and with improvements in the dis-
tribution and localisation of occludin and zonula occludens 1 (Fig. 1) [23]. Among the mechanisms
implicated in the regulation of gut permeability and thereby in systemic inﬂammation by the gut
microbiota, enteroendocrine peptides produced by the host constitute an attractive track. Interestingly,
we could associate these positive effects of gut microbiota modulations by prebiotics on gut perme-
ability with an increase in the endogenous production of an enteroendocrine peptide implicated in the
regulation of intestinal epithelial proliferation and gut barrier integrity, namely, the glucagon-like
peptide-2 (GLP-2) (Fig. 1). More speciﬁcally, we have shown that GLP-2 antagonist treatment
completely blocked the major features (improvements in gut barrier function and reductions in
metabolic endotoxaemia and inﬂammation induced by prebiotics) of gut microbiota modulations in
the pathology of obesity and type 2 diabetes, thereby strongly suggesting that the beneﬁcial changes in
gut microbiota control inﬂammation through a mechanism involving the GLP-2-driven improvement
of gut barrier functions in obesity and type 2 diabetes [23]. Among the mechanisms implicated in GLP-
2 increase, we recently determined that an increase in proglucagon (GLP-2 precursor) expression upon
gut microbiota modulation is associated with an increase in the number of cells producing this
enteroendocrine peptide, the epithelial enteroendocrine L-cells (Fig. 1) [54]. Moreover, by combining
high-throughput methods (i.e., pyrosequencing and phylogenetic microarrays), we found that prebi-
otic treatment changes 102 gut bacterial taxa, and the abundance of 25 taxa was positively or nega-
tively correlated with the number of L-cells in the intestine [54]. More important, we found that
Akkermansia muciniphila was increased by approximately 100-fold [64]. It is worth noting that
Akkermansia muciniphila represents from 3 to 5% of the microbial community [64,65] in healthy
subjects and that the abundance of this bacteria is inversely correlated with body weight [61,66–69],
type 1 diabetes [70] or bowel diseases [71] in both mice and humans. Whether this bacteria plays a
major role in the context of gut barrier dysfunction and type 2 diabetes merits future investigation.
Importantly, gut microbiota modulations using prebiotics in the context of obesity and type 2
diabetes not only abolished gut permeability, endotoxaemia and inﬂammation but also decrease body
weight and fat mass accumulation and improve glucose homeostasis (glucose tolerance and insulin
resistance), lipid metabolism and leptin sensitivity [20,21,54,63,72]. Interestingly, these beneﬁcial ef-
fects may be associated with level changes in other enteroendocrine peptides involved in glucose
homeostasis, appetite and/or body weight regulation. Indeed, we have demonstrated that prebiotic-
induced changes in the gut microbiota also modulate glucagon-like peptide-1 (GLP-1), peptide YY
(PYY), glucose-dependent insulinotropic polypeptide (GIP) and ghrelin [23,54,62,63,72,73]. Notably,
the invalidation of the GLP-1 receptor suppresses the improvements in glucose homeostasis by pre-
biotics in obesity and type 2 diabetes, thereby showing that GLP-1 plays a key role in the improvement
associated with prebiotic feeding (Fig. 1) [20].
Human intervention studies
The implication of gut peptides in the beneﬁcial crosstalk between the gutmicrobiota and host have
also been demonstrated in humans. First demonstrated in healthy subjects, the gut fermentation of
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also shown that the prebiotic treatment of healthy subjects was associated with an increase in satiety
and a decrease in hunger sensation [75]. We related these changes in appetite sensation with higher
GLP-1 and PYY plasma levels [76]. Interestingly, in healthy humans, the gut fermentation of prebiotics
is associated with a decrease in the postprandial plasma glucose response [76]. More recently, Parnell
and Reimer demonstrated that gut microbiota modulations (after 12 weeks of prebiotic treatment)
modulated ghrelin and PYY in overweight and obese patients and could thereby promote weight loss
and improve glucose regulation [77].
Among the metabolites produced by the gut microbiota, the short chain fatty acids (SCFAs) could
be a link between the gut microbiota and changes in gut peptides levels. Indeed, the modulation of
plasma SCFAs after gut microbiota fermentation was related to changes in the gut peptides regu-
lating appetite in insulin-resistant subjects [78]. The modulation of SCFA production by prebiotics
has also been reported in another human study performed by Lecerf et al [79]. They found modi-
ﬁcations in acetate, butyrate, propionate and total SCFA levels in the faecal samples of healthy
humans treated with xylo-oligosaccharides alone or with an inulin/xylo-oligosaccharide mixture.
Furthermore, the inulin/xylo-oligosaccharide mixture decreased the plasma LPS levels and reduced
the pro-inﬂammatory effects of LPS on cytokine gene expression in the blood of healthy humans
[79].
In humans, changes in the gut peptides involved in glucose homeostasis and regulation in food
intake occur upon gut microbiota modulations, but their effects on gut permeability, metabolic
endotoxaemia and inﬂammation in obesity and type 2 diabetes remain to be demonstrated. Moreover,
more studies are needed to unravel the beneﬁcial effects of prebiotics and of the associated speciﬁc
bacterial composition and/or activity with improved parameters under prebiotic treatment in obese
and type 2 diabetic patients.
With respect to this aim, we recently performed a double-blind intervention study with inulin-type
fructans in obese women for 3 months. The prebiotic treatment and not the placebo led to an increase
in Biﬁdobacterium and Faecalibacterium prausnitzii [80]. As mentioned earlier, these bacteria have been
reported to be decreased in type 2 diabetes and to correlate with anti-inﬂammatory effects. Inter-
estingly, in our study, both bacteria were negatively correlated with metabolic endotoxaemia [80]. In
another study, Malaguarnera et al reported a decrease in metabolic endotoxaemia in non-alcoholic
steatohepatitis patients treated with Biﬁdobacterium longum and prebiotics (oligofructose) in addi-
tion to lifestyle modiﬁcations [81].
Conclusions
Obesity and type 2 diabetes are becoming worldwide epidemics. The current clinical management
of obesity is based on targeting dietary habits, energy expenditure and related disorders (e.g., glucose
intolerance, type 2 diabetes, and hypertension), but most of the therapeutic interventions are un-
successful. Among the potential environmental factors that contribute to the onset of diseases asso-
ciated with obesity, unequivocal experimental evidence has revealed the role of a ‘novel’ partner, the
gut microbiota. Various studies demonstrate a link between the gut microbiota composition and body
weight. However, the exact composition and/or the metabolic activity of the gut microbial community
that contribute to the onset of obesity and type 2 diabetes remain unknown. Evidence suggests that
enteroendocrine cell metabolism and the endocannabinoid system are controlled by the gut micro-
biota and constitute a link among gut barrier dysfunction, metabolic endotoxaemia and low-grade
inﬂammation. However, detailed studies are needed to verify whether these mechanisms occur in
humans. Recent studies have demonstrated the beneﬁcial effects of prebiotic treatment on glucose,
lipids and inﬂammatory markers in obese subjects. Interestingly, these metabolic improvements
are positively correlated with changes in speciﬁc microbes (i.e., Biﬁdobacterium spp., Lactobacillus spp.,
F. prausnitzii and A. muciniphila).
Thus, nutrients with prebiotic properties, such non-digestible carbohydrates, change the gut
microbiota and improve the metabolic disorders associated with obesity and type 2 diabetes (e.g., gut
permeability, metabolic endotoxaemia, and inﬂammation). Although this concept is well established in
rodents, more detailed studies in humans enrolling more patients are needed.
Practice points
 Gut microbiota composition is directly dependent on nutrient intake (e.g., fat, digestibility of
carbohydrates)
 Metabolic endotoxaemia and gut barrier dysfunction are involved in the onset of metabolic
diseases associated with obesity
 Prebiotic-induced changes in the gut microbiota improve glucose, lipid and inﬂammation
homeostasis
Research agenda
 The exact taxonomic composition of the gut microbiota or associated metabolic functions
needs to be deﬁned to design novel targeted approaches
 Detailed studies are necessary to study gut permeability and related gut barrier dysfunctions
in obese and type 2 diabetic patients
 The role of ‘novel’ beneﬁcial microbes (e.g., F. prausnitzii and A. muciniphila) as therapeutic
tools warrants controlled human studies
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